Neuland Laboratories Share Price

    NSE
    0.00
    0.00 (0.00%)
    NEULANDLAB
    BUY

    1Y Annualised Return

    71.04%

    3Y Annualised Return

    122.73%

    5Y Annualised Return

    84.85%

    The current prices are delayed, login or Open Demat Account for live prices.

    Neuland Laboratories Stock Performance

    1W Return15.95
    1Y Return68.21
    Today's Low14100
    Prev. Close14,503.00
    Mkt Cap (Cr.)18,299.27
    1M Return16.27
    3Y Return1,036.04
    52-Week High18100
    Open14,503.00
    PE Ratio88.06
    6M Return4.48
    Today's High14599
    52-Week Low7920.1
    Face Value10

    Neuland Laboratories Company background

    Founded in: 1984
    Managing director: D Saharsh Rao
    Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao. The Company is engaged in manufacturing and selling of bulk drugs such as Salbutamol Sulphate, Terbutaline Sulphate, Labetalol Hydrochloride and Ciprofloxacin. Neuland Drugs Pharmaceuticals Pvt. Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992. NLL manufactures bulk drugs.The Company came out with its initial public offering in Apr.94 at a premium of Rs 35 aggregating Rs 5.69 cr, to partfinance the capacity expansion to manufacture bulk drugs and to diversify its productmix. The cost of the project as estimated by ICICI was Rs 15.7 cr.NLLs products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate.During the year 19992000, the company introduced Itraconazole, an antifungal drug and Ipratropium Bromide, an antiasthmatic drug and the R D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form.Mirtrazapine, an antidepressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI.The Company commenced commercial production of Ramipril, a cardiovascular drug for export to certain markets in 2002.The Company commenced commercial production of Citalopram Hydrobromide, an anti depressant, Pirbuterol Acetate, a bronchodilator, Levofloxacin, an anti bacterial, Levetiracetam, an anti convulsant in 2003.A subsidiary company of Neuland Laboratories Ltd was incorporated on January 4, 2007 in the State of Delaware, USA with its principal office in Orange County, California. During the year 20082009, Neuland Laboratories K.K., Japan was incorporated as a subsidiary of Company.During 201213, Company undertook a major reorganisation of businesses aimed at deleveraging on one hand and on other hand narrowing the focus on core activities: APIs, Intermediates and Contract Manufacturing. Consequently, the Company divested its RD activities by selling its Land and Building and some identified intellectual properties to Neuland Pharma Research Private Limited and its Peptides Research activities along with identified intellectual properties to Neuland Health Sciences Private Limited. It entered into a Joint Business Arrangement with API Corporation, Japan, a part of Mitsubishi Chemical, for manufacturing and sale of APIs and Intermediates.During 201314, the Company enhanced its product bouquet by launching 5 more products. It also enhanced its development portfolio to 22 molecules/ APIs created for launch between 2013 and 2016. It opened new office in New Jersey, provide them with quick support and coordinate in various business activities.In 2018, the Board of Directors of the Company approved the Scheme of Amalgamation of Neuland Health Sciences Private Limited and Neuland Pharma Research Private Limited with the Company, on April 1, 2016, the Appointed Date of Scheme. Pursuant to the Scheme of Amalgamation, 45,90,608 equity shares held by Neuland Health Sciences Private Limited in the Company were cancelled and the Company allotted 68,61,243 equity shares to the shareholders of Neuland Health Sciences Private Limited and Neuland Pharma Research Private Limited on April 13, 2018 and further 1,675,000 equity shares were issued and allotted under Qualified Institutional Placement (QIP). The Company acquired Advanced Intermediates and API facility Unit 3, with a capacity of about 197 kiloliters at Gaddapotharam Village, in Sanga Reddy District, in 201819. The Unit III was commercialised with 320 kL reaction volume in FY 2023.

    As of , Neuland Laboratories share price is ₹14263. The stock opened at ₹14503 and had closed at ₹14503 the previous day. During today’s trading session, Neuland Laboratories share price moved between ₹14,100.00 and ₹14,599.00, with an average price for the day of ₹14349.50. Over the last 52 weeks, the stock has recorded a low of ₹7,920.10 and a high of ₹18,100.00. In terms of performance, Neuland Laboratories share price has increased by 4.5% over the past six months and has increased by 71.04% over the last year.

    Read More
    Neuland Laboratories SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years
    Total Investment of ₹65,00,000
    Would have become ₹94,76,026 (+45.79%)
    Daily SIP of 25,000 would have become 94,76,026 in 1 year with a gain of 29,76,026 (+45.79%)
    View details of Market Depth

    Neuland Laboratories Fundamental

    Market Cap (in crs)

    18,299.27

    Face Value

    10

    Turnover (in lacs)

    8,263.13

    Key Metrics

    Qtr Change %
    80.09% Gain from 52W Low
    11.2
    Dividend yield 1yr %
    Low in industry
    0.1

    Neuland Laboratories Key Financials

    View more
    Loading chart...
    Loading chart...
    Loading chart...
    Loading chart...
    Neuland Laboratories Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    328.36 Cr
    398.03 Cr
    310.84 Cr
    439.6 Cr
    385.01 Cr
    Neuland Laboratories Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    1497.35 Cr
    1571.12 Cr
    1200.95 Cr
    953.15 Cr
    953.01 Cr
    766.6 Cr
    Neuland Laboratories Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    27.81 Cr
    101.59 Cr
    32.84 Cr
    97.87 Cr
    67.56 Cr
    Neuland Laboratories Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    260.11 Cr
    300.08 Cr
    163.52 Cr
    63.82 Cr
    80.63 Cr
    16.21 Cr

    Neuland Laboratories Result Highlights

    • Neuland Laboratories Ltd reported a 2.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 6.0%.

    • Its expenses for the quarter were down by 9.6% QoQ and 2.2% YoY.

    • The net profit decreased 33.5% QoQ and decreased 20.1% YoY.

    • The earnings per share (EPS) of Neuland Laboratories Ltd stood at 52.7 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Neuland Laboratories

    Promoter
    32.7%
    Foreign Institutions
    21.7%
    Mutual Funds
    7.7%
    Domestic Institutions
    12%
    Public
    33.7%
    Promoter
    32.7%
    Foreign Institutions
    22.1%
    Mutual Funds
    7.4%
    Domestic Institutions
    11.4%
    Public
    33.8%
    Promoter
    32.7%
    Foreign Institutions
    23.9%
    Mutual Funds
    6.3%
    Domestic Institutions
    9.5%
    Public
    34%
    Promoter
    32.6%
    Foreign Institutions
    26.5%
    Mutual Funds
    4%
    Domestic Institutions
    6.7%
    Public
    34.1%
    Promoter
    32.7%
    Foreign Institutions
    25.7%
    Mutual Funds
    4.1%
    Domestic Institutions
    6.8%
    Public
    34.8%
    Promoter
    32.7%
    Foreign Institutions
    24.4%
    Mutual Funds
    3.9%
    Domestic Institutions
    7%
    Public
    35.9%

    Neuland Laboratories Technical Analysis

    Moving Averages Analysis
    0.00
    Current Price
    Bullish Moving Averages
    15
    Bearish Moving Averages
    1
    5Day EMA
    14,156.50
    10Day EMA
    13,605.60
    12Day EMA
    13,445.60
    20Day EMA
    13,041.30
    26Day EMA
    12,866.60
    50Day EMA
    12,543.60
    100Day EMA
    12,450.70
    200Day EMA
    12,092.10
    5Day SMA
    14,593.60
    10Day SMA
    13,260.90
    20Day SMA
    12,639.80
    30Day SMA
    12,681.90
    50Day SMA
    12,264.20
    100Day SMA
    12,028.80
    150Day SMA
    12,626.90
    200Day SMA
    13,138.70
    Delivery & Volume
    Loading chart...

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    15150 Rs
    64193 Rs
    Week Rs
    84504 Rs
    520871 Rs
    Month Rs
    33342 Rs
    158224 Rs
    14,320.67
    Pivot
    Resistance
    First Resistance
    14,541.33
    Second Resistance
    14,819.67
    Third Resistance
    15,040.33
    Support
    First Support
    14,042.33
    Second support
    13,821.67
    Third Support
    13,543.33
    Relative Strength Index
    64.03
    Money Flow Index
    79.36
    MACD
    578.96
    MACD Signal
    294.82
    Average True Range
    648.08
    Average Directional Index
    28.61
    Rate of Change (21)
    16.80
    Rate of Change (125)
    4.42
    Name
    Holding Percent
    HSBC BALANCED ADVANTAGE FUND
    2.39
    ICICI PRUDENTIAL S&P BSE 500 ETF
    1.78
    MALABAR INDIA FUND LIMITED
    5.76
    JUPITER INDIA FUND
    1.29
    MATTHEWS INDIA FUND
    1.04

    Neuland Laboratories Latest News

    15 JUL 2025 | Tuesday

    Neuland Laboratories Ltd - 524558 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    15 JUL 2025 | Tuesday

    Neuland Laboratories Ltd - 524558 - Disclosure Under Regulation 30 Of SEBI Listing Regulations

    15 JUL 2025 | Tuesday

    Neuland Laboratories Ltd - 524558 - Clarification sought from Neuland Laboratories Ltd

    View More

    Neuland Laboratories Share Price FAQs

    Neuland Laboratories share price in the past 1-year return was 68.2. The Neuland Laboratories share hit a 1-year low of Rs. 7920.1 and a 1-year high of Rs. 18100.

    The market cap of Neuland Laboratories is Rs. 18299.27 Cr. as of 18/7/2025.

    The PE ratios of Neuland Laboratories is 88.06 as of 18/7/2025.

    The PB ratios of Neuland Laboratories is 12.04 as of 18/7/2025

    The Mutual Fund Shareholding in Neuland Laboratories was 7.66% at the end of 18/7/2025.

    You can easily buy Neuland Laboratories shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Neuland Laboratories share price is ₹18100 and ₹7920.1 as of 18/7/2025.

    Please be aware that Neuland Laboratories stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    65.06
    -1.20 (-1.81%)
    133.84
    -1.07 (-0.79%)
    680.25
    -1.45 (-0.21%)
    2,596.10
    -20.50 (-0.78%)
    157.39
    -1.85 (-1.16%)
    376.00
    -5.45 (-1.43%)
    162.37
    +2.47 (+1.54%)
    257.20
    -2.45 (-0.94%)
    394.75
    -9.45 (-2.34%)
    407.90
    -5.55 (-1.34%)
    Top Gainers
    266.95
    +6.35 (+2.44%)
    942.00
    +18.70 (+2.03%)
    162.37
    +2.47 (+1.54%)
    246.31
    +2.44 (+1.00%)
    2,472.20
    +23.10 (+0.94%)
    Top Losers
    1,099.30
    -60.50 (-5.22%)
    645.50
    -19.95 (-3.00%)
    394.75
    -9.45 (-2.34%)
    739.50
    -12.30 (-1.64%)
    1,901.00
    -28.90 (-1.50%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -